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Abstract
Intestinal fibrosis and stenosis are common complications of Crohn’s disease [CD], frequently 
requiring surgery. Anti-inflammatory strategies can only partially prevent fibrosis; hence, anti-
fibrotic therapies remain an unmet clinical need. Oxysterols are oxidised cholesterol derivatives with 
important roles in various biological processes. The enzyme cholesterol 25-hydroxylase [CH25H] 
converts cholesterol to 25-hydroxycholesterol [25-HC], which modulates immune responses and 
oxidative stress. In human intestinal samples from CD patients, we found a strong correlation 
of CH25H mRNA expression with the expression of fibrosis markers. We demonstrate reduced 
intestinal fibrosis in mice deficient for the CH25H enzyme, using the sodium dextran sulphate 
[DSS]-induced chronic colitis model. Additionally, using a heterotopic transplantation model of 
intestinal fibrosis, we demonstrate reduced collagen deposition and lower concentrations of 
hydroxyproline in CH25H knockouts. In the heterotopic transplant model, CH25H was expressed 
in fibroblasts. Taken together, our findings indicate an involvement of oxysterol synthesis in the 
pathogenesis of intestinal fibrosis.
Key Words: Fibrogenesis; intestinal fibrosis; cholesterol 25 hydroxylase [CH25H]; oxysterols; transplantation; graft; mouse model
1. Introduction
Crohn’s disease [CD] is a major form of inflammatory bowel disease 
[IBD], characterised by chronic discontinuous inflammatory le-
sions. Inflammation in CD is typically transmural and can affect the 
whole gastrointestinal tract, with a preference for the small intestine. 
Common complications in CD patients include perforations of the 
gut wall [fistulae and abscesses] as well as intestinal fibrosis and 
strictures with narrowing of the intestinal lumen. More than 60% 
of CD patients have to undergo surgery within 20 years following 
the initial diagnosis,1 and recurrent disease requires more surgical 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.  
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procedures in at least 50% of the patients after the first operation.2,3 
The second major form of IBD, ulcerative colitis [UC], character-
ised by continuous inflammatory lesions of the colon, has been con-
sidered a non-fibrotic disease; but recent evidence indicates some 
degree of submucosal fibrosis in up to 100% of UC colectomy spe-
cimens,4,5 and the degree of fibrosis seems to be proportional to the 
degree of chronic but not active inflammation.6
Currently, no drugs have been approved for treatment or preven-
tion of intestinal fibrosis.7,8 Anti-inflammatory medications, including 
anti-tumour necrosis factor [TNF] antibodies or immunosuppres-
sants, are only partially effective in preventing fibrosis,9 and new pre-
ventive and therapeutic strategies are therefore urgently needed.
On a molecular level, fibrosis is characterised by excessive 
accumulation of extracellular matrix [ECM] components includ-
ing collagen and laminin, replacing the original tissue and leading 
to stiffening and loss of normal function.10,11 Transforming growth 
factor-β [TGF-β] is a key driver of fibrosis, promoting differen-
tiation of fibroblasts to myofibroblasts, indicated by expression 
of α-smooth muscle actin [SMA].12,13 Myofibroblasts are the main 
effector cells for fibrosis and mainly responsible for ECM deposi-
tion.14–16 On the other hand, myofibroblasts also synthesise matrix 
metalloproteinases [MMPs] as ECM-degrading enzymes, and their 
inhibitors [tissue inhibitors of MMPs, TIMPs]. Myofibroblasts can 
derive from the local fibroblast pool; however, epithelial, endothelial, 
haematopoietic cells, or pericytes can also differentiate into myofi-
broblasts.16 Nevertheless, the chain of events leading to intestinal 
fibrosis is insufficiently understood.
Studying the pathophysiology of intestinal fibrosis has been 
limited by the lack of a bona fide animal model. Chronic dextran so-
dium sulphate [DSS] colitis is frequently used as a fibrosis model,17,18 
even though key aspects of CD-associated intestinal fibrosis, such 
as occlusion of the intestinal lumen, are not observed in this model. 
Recently, we established and characterised a murine heterotopic 
transplant model, where small intestinal sections are transplanted 
into the neck fold of recipient mice.19,20 In the transplanted sections, 
the lumen progressively occludes, accompanied by expression of 
TGF-β and α-SMA as well as collagen deposition in the extracellular 
matrix. In this model, we previously demonstrated that pirfenidone, 
an anti-inflammatory and anti-fibrotic drug approved for the treat-
ment of idiopathic pulmonary fibrosis, was able to reduce fibrosis.20
Oxysterols are increasingly recognised as immune-modulatory 
molecules. 25-Hydroxycholesterol [25-HC] is part of the rapid 
innate immune response and an efficient defence molecule. 25-HC 
can induce macrophage activation,21–23 T cell differentiation,24 
and production of IL-825–27 as well as IL-6,23 and was shown to 
have strong antiviral activity against many enveloped viruses.28–30 
Furthermore, Dang and colleagues recently demonstrated a criti-
cal role of 25-HC in inhibiting activation of the DNA sensor pro-
tein AIM2, preventing spurious AIM2 inflammasome activation.31 
Cholesterol 25-hydroxylase [CH25H] is the key enzyme mediating 
hydroxylation of cholesterol to 25-HC.32 25-HC is rapidly pro-
duced in vivo upon immune stimulation by toll-like receptor [TLR] 
agonists including lipopolysaccharide [LPS] and poly[I:C].28,30,33,34 
25-HC production was shown to be increased in the airways of 
patients with chronic obstructive pulmonary disease [COPD] and 
correlated with the degree of neutrophilic infiltration.35 25-HC can 
be further hydroxylated to di-hydroxy cholesterols [e.g., 7α, 25-HC] 
which have been shown to act as chemoattractants for cells of the 
adaptive and innate immune system.36,37
Recently, CH25H expression was shown to be upregulated in pri-
mary lung fibroblasts in response to activated eosinophils, suggesting 
CH25H activation in chronic lung diseases including COPD.38 Pro-
fibrotic effects of the CH25H product 25-HC have been demonstrated 
in vitro. In a tissue culture model using human fetal lung fibroblasts 
[HLF], 25-HC induced nuclear factor-κB [NF-κB] activation with 
subsequent release of TGF-β, leading to myofibroblast formation, 
MMP-2 and 9 release, SMA expression, and collagen production.39 
However, the role of 25-HC in intestinal inflammation and fibrosis 
has not been addressed. In this study, we aimed to investigate the role 
of the enzyme CH25H in the development of intestinal fibrosis.
2. Materials and Methods
2.1. Human tissue from patients with CD and 
controls
Intestinal tissue was obtained from patients with CD undergoing ile-
ocaecal resection due to stenosis in the terminal ileum. Non-fibrotic 
samples originate from the margin of the resections and fibrotic 
samples from the thickened fibrosis-affected region. Healthy control 
samples were obtained from patients undergoing right-sided hemi-
colectomy due to adenocarcinoma [non cancer-affected ileal resec-
tion margin]. A power analysis demonstrated that seven cases with a 
score of 4 [standard deviation of 2] and five controls with a score of 
1 [standard deviation of 0.5] would have 90% power to detect this 
difference at a significance level of 0.05 with a Mann-Whitney U test 
in a one-sided analysis [G*Power Version 3.1.9.2].40
Immediately after resection, samples were fixed in Tissue-Tek® 
[O.C.T. Compound, Sakura® Finetek], frozen in isopentane on dry 
ic,e and stored at -80°C for RNA extraction.
2.2. Animals
CH25H-deficient mice [Ch25h-/-] in a C57BL/6 background were 
kindly provided by Novartis Institutes for BioMedical Research,33 
and bred in our animal facility with C57BL/6 mice to generate 
Ch25h+/- mice. Ch25h+/- were then crossed to obtain Ch25h-/- and 
Ch25h+/+ [wild-type] littermates. The animals received standard lab-
oratory mouse food and water ad libitum. They were housed under 
specific pathogen-free [SPF] conditions in individually ventilated 
cages; 7- to 10-week old female littermates were used for all studies.
2.3. DSS-induced chronic colitis
DSS-induced chronic colitis was induced by administration of four 
cycles of treatment with DSS [MP Biomedicals]. Every cycle con-
sisted of 7 days of 2.5% DSS followed by 10 days of normal drink-
ing water. Mice were killed 4 weeks after the last DSS cycle. The 
colon was fixed and embedded and cut transversally. Microscopy 
images were acquired from the last <1-cm parts of the colon, 
avoiding squamous cell epithelial sections [which are occasionally 
observed] and oblique sections. Colonoscopy was scored using the 
murine endoscopic index of colitis severity [MEICS] scoring sys-
tem.41 Histological scoring was performed on haematoxylin and 
eosin [HE]-stained distal colon sections, as described previously.41,42 
The investigator was blinded during image acquisition and scoring.
2.4. Heterotopic intestinal transplant model
The heterotopic mouse intestinal transplant model is an adaptation 
of the transplantation model of intestinal fibrosis in rats, which have 
both been described in detail previsously.19,20 Briefly, donor small 
bowel was resected and transplanted subcutaneously into the neck 
of a recipient animal of the same gender and genotype. A single dose 
of cefazolin [Kefzol, 1 g diluted in 2.5 ml aqua dest.] was applied 
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intraperitoneally [i.p.] as infection prophylaxis. The time interval 
between graft resection and subsequent implantation was less than 
15  min. No anaesthesia-related recipient death, post-transplanta-
tion recipient death, or evidence of infection was observed in any 
of the animals. Intestinal grafts were removed 7  days after trans-
plantation. At explantation, each graft was divided into three equal 
segments. One segment was fixed in 4% formalin and prepared for 
histopathological assessment. The remaining segments were snap-
frozen in liquid nitrogen and stored at -80°C for RNA extraction 
and hydroxyproline [HYP] assay, respectively.
For each sample, 10 mg of snap-frozen tissue was homogenised 
with 100 µl of ultrapure water in M tubes [Miltenyi Biotec], using 
a gentleMACS tissue homogeniser [Miltenyi Biotec]. Graft collagen 
content was evaluated using the HYP Assay Kit [Sigma-Aldrich] 
according to the manufacturer’s instructions. HYP concentration 
is determined by the reaction of 4-[dimethylamino]benzaldehyde 
[DMAB] with oxidised HYP, resulting in a colourimetric product 
[560  nm], proportional to the presence of HYP. All samples and 
standards were run in duplicate, and absorbance at 560  nm was 
detected on a SpectraMax M2 fluorescence microplate reader using 
SoftMax Pro version 5 Software [Molecular Devices].
2.5. RNA isolation, cDNA synthesis, and real-time 
polymerase chain reaction
Total RNA was isolated using the RNeasy Plus Mini Kit [QIAGEN]. 
For mouse samples, lysis buffer from the kit was added to snap-
frozen resections, and samples were shredded in M tubes [Miltenyi 
Biotec] in a gentleMACS tissue homogeniser [Miltenyi Biotec]. 
For human samples 10-μm thick tissue tek sections, containing 
the full thickness of the intestinal wall [confirmed by H/E stain-
ing], were cut using a cryostat. Sections were dissolved in TRIzol 
[Invitrogen, Life Technologies]. Total RNA was prepared accord-
ing to the manufacturer’s instructions. On-column DNase digestion 
with RDD buffer [QIAGEN] was performed for 15  min at room 
temperature. RNA concentration was determined by absorbance 
at 260 and 280 nm. Complementary DNA [cDNA] synthesis was 
performed using a High-Capacity cDNA Reverse Transcription Kit 
[Applied Biosystems] following the manufacturer’s instructions. 
Real-time polymerase chain reaction [PCR] was performed using the 
TaqMan Fast Universal Master Mix [Applied Biosystems] on a Fast 
7900HT Real-Time PCR System, and results analysed with the SDS 
software [Applied Biosystems]. The real-time PCR started with an 
initial enzyme activation step [5 min, 95°C], followed by 45 cycles 
consisting of a denaturing [95°C, 15 s] and an annealing/extending 
[60°C, 1 min] step. For each sample, triplicates were measured and 
glyceraldehyde-3-phosphate dehydrogenase [GAPDH] was used as 
endogenous control. Results were analysed by the ∆∆CT method. 
All gene expression assays were obtained from Life Technologies.
2.6. Analysis of microscopy images
Sections were examined using an AxioCam HRc [Zeiss] on a Zeiss 
Axio Imager.Z2 microscope with AxioVision release 4.8.2 software. 
Collagen layer thickness was measured on Sirius Red-stained slides 
in at least eight fields in representative areas at 100-fold magnifi-
cation, by an investigator blinded to the experiment. The muscu-
laris mucosae and the external muscle layer were quantified by a 
similar procedure, with an investigator blinded to the genotype of 
the animals. Great effort was made by the investigator and the ad-
vising gastrointestinal pathologist [SL] to restrict measurements to 
horizontally cut sections of the colon and also in colon sections in 
animals with DSS colitis [which typically leads to a disrupted crypt 
architecture]. For the automated microscopy analysis of DSS colitis, 
Sirius Red-stained slides were analysed by bright-field microscopy, 
and images were acquired by an investigator blinded to the geno-
type. The images were analysed using MATLAB software, version 
8.6 R2015b [MathWorks]. Customised scripts identified the col-
lagen layer of each image by clustering pixels of similar colours in 
five clusters, using the k-means clustering algorithm. Wild-type and 
knockout animals were used in the same batch with the same set-
tings, to ensure an objective and unbiased analysis.
Microscopy images for the heterotopic transplant model were 
acquired and analysed in a similar manner, except that a polarising 
filter was used. Under polarised light, Sirius Red-stained collagen 
assumes a palette of colours ranging from green to red, based on 
the fibrotic maturation process. Our MATLAB scripts identified two 
cluster of pixels [collagen and non-collagen] using highly similar 
k-means clustering algorithms.
2.7. Western blot
Tissue was lysed in M-PER cell lysis buffer [Thermo Fisher 
Scientific]. Protein levels were determined by bicinchoninic acid 
[BCA] assay according to the manufacturer’s instructions, and equal 
amounts of protein were loaded onto SDS/PAGE gels. Western blots 
were performed using monoclonal rabbit anti-mouse TGF-β anti-
bodies [3711S, Bioconcept, 1:1000], polyclonal rabbit anti-mouse 
β-actin antibodies [4970, 13E5, Cell Signaling, 1:2000], polyclonal 
goat anti-mouse α-SMA antibodies [PA5-18292, Thermo Fisher 
Scientific, undiluted], and the horseradish peroxidase-conjugated 
secondary goat anti-rabbit antibody [sc-2004, Santa Cruz, 1:2000]. 
Luminescence of Western blots was quantified densitometrically 
with ImageJ software.
2.8. Mass cytometry analysis
Data were acquired on a CyTOF-2.1 mass cytometer [Fluidigm] 
with an acquisition flow rate of 0.03  ml/min. The following 
signal processing settings were used: default thresholding scheme, 
lower convolution threshold of 800 intensity units [IU], minimum 
event duration of eight pushes, maximum event duration of 100 
pushes, noise reduction active. All samples were spiked with EQ 
four-element calibration beads during acquisition [Fluidigm; cat. 
no. 201078] and resulting FCS [Flow Cytometry Standard] files were 
normalised with the built-in normalisation algorithm [Helios soft-
ware version 6.5.358] to account for intra- and intersample intensity 
measurement variability. The data were analysed and visualised with 
Cytobank software [Cytobank Inc.] and software packages for R 
programming language flowCore, flowSOM and ggplot2.
2.9. RNA in situ hybridisation [RNAscope]
Ch25h mRNA localisation in the murine small intestine was as-
sessed by RNA in situ hybridisation. Fresh small intestine sections 
and intestine grafts were harvested and incubated for 24 h in 4% 
paraformaldehyde/PBS [PFA/PBS]. The PFA/PBS solution was re-
placed by 10% sucrose in PBS up to the tissue sink to the bottom 
of the container. This step was repeated with 20% and 30% su-
crose solutions, and the tissue was embedded in Optimal Cutting 
Temperature [OCT]. Sections [3–4 µm] were prepared on Superfrost 
microscope slides [Thermo Fisher Scientific, Braunschweig, 
Germany]. The RNA in situ hybridisation was performed using 
the RNAscope 2.5 HD assay, Red [Advanced Cell Diagnostics, 
Hayward, CA, USA] following the manufacturer’s instructions. 
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In brief, slides were rehydrated in PBS and were subjected to pre-
treatment solutions using the recommended incubation time and 
temperature. Next, slides were incubated for 2  h with a Ch25h 
probe designed and provided by the supplier. The tissue and assay 
quality were tested with a positive control probe Peptidyl-prolyl 
cis-trans isomerase B [Ppib, data not shown] and a negative control 
probe for the bacterial gene Dihydrodipicolinate reductase [Dapb]. 
Four signal amplification steps were carried out at 40°C, followed 
by two additional steps at room temperature with the appropriate 
solutions. The fifth amplification step was extended from 30 min 
to 1 h in order to enhance the chromogenic signal. Detection of 
chromogenic signals was achieved by using the Fast-Red reagent 
for 10  min. Slides were counterstained with haematoxylin I  and 
mounted with VectaMount Mounting Medium HT-5000 [Vector 
Laboratories, Burlingame, CA, USA].
2.10. Immunohistochemistry
Three-µm consecutive section pairs of intestinal grafts were pre-
pared for in situ hybridisation and immunohistochemistry. Sections 
used for immunohistochemistry were blocked with Avidin/Biotin 
blocking reagents [Avidin/Biotin blocking kit, Vector Laboratories, 
Burlingame, CA, USA], and with one drop of Bloxall [Vector 
Laboratories, Burlingame, CA, USA] as described by the manufac-
turer. After washing once with PBS for 5 min, sections were blocked 
with 2% BSA for 15 min and incubated with 1:400 rabbit anti-αSMA 
antibody [ab5694, Abcam, Cambridge, UK] overnight at 4 °C. Next, 
slides were washed twice with hypertonic PBS [18 g NaCl /L] for 
5 min and sections were incubated at room temperature for 1 h with 
1:500 secondary antibody Biotin-SP-conjugated donkey anti-rabbit 
IgG [H+L] [Jackson ImmunoResearch, West Grove, PA, USA]. Slides 
were washed twice in PBS, and the immunohistochemical staining 
was obtained by incubating graft sections for 40 min with Vecstatin 
Elite ABC reagent [Vector Laboratories, Burlingame, CA, USA]. ABC 
solution was washed twice with PBS and replaced by DAB solu-
tion for 1 min [prepared as described by the manufacturer: Vector 
Laboratories, Burlingame, CA, USA]. After washing for 5  min in 
water, sections were counterstained with haematoxylin [Hämalaun 
verstärkt nach Mayer, Artechemis AG, Zofingen, Switzerland] and 
Eosin Y [HT110132, Sigma-Aldrich, Steinheim, Germany], followed 
by dehydration in alcohol gradient [dipping in 70%, 96%, and 
100% ethanol]. Mounting was performed as described for in situ 
hybridisation.
2.11. In vitro experiments
3T3 cells were maintained in high glucose Dulbecco’s Modified 
Eagle Medium [DMEM, Life Technologies] supplemented with 
10% fetal calf serum [FCS] and kept at 37°C in a humidified at-
mosphere containing 5% CO2. Murine primary fibroblasts were 
isolated and cultured as described previously.43 The isolated 
cells were cultured in 25-cm2 culture flasks [Costar, Bodenheim, 
Germany] with DMEM containing 10% FCS, penicillin [100 IE/
mL], streptomycin [100  g/mL], ciprofloxacin [8  g/mL], gentamy-
cin [50 g/mL], and amphotericin B [1 g/mL] at 37°C in a humidi-
fied atmosphere containing 10% CO2. Non-adherent cells were 
removed. Once fibroblasts reached 90% confluence, FCS-free 
DMEM-medium was added and they were starved for 24 h before 
compound treatment. Cells were stimulated by treatment for 72 h 
with 5 ng/ml TGF-β [130-095-067, Miltenyi Biotec], 0.001–10 μM 
25-HC [H1015, Sigma-Aldrich], or a combination of the two com-
pounds as indicated.
2.12. Statistical analysis
Data are presented as mean  ±  standard error of the mean [SEM] 
unless otherwise indicated. Correlation was assessed using non-
parametric Spearman rank analysis. Significance of group-wise com-
parisons was assessed using the Kruskal-Wallis test, Mann-Whitney 
U test or the unpaired t test with p  <0.05 considered statistically 
significant [***p <0.001, ** p <0.01, * p <0.05].
2.13. Study approval
For patient data, written informed consent was obtained for an-
onymous use of patient data and resected parts of human intestine 
according to the code of conduct for responsible use of surgical 
rest material (Research Code University Medical Center Groningen 
[http://www.rug.nl/umcg/research/documents/ research-code-info-
umcg-nl.pdf, see Code goed gebruik voor gecodeerd lichaamsmateri-
aal]). Mouse experiments were approved by the local animal welfare 
authority [Tierschutzkommision Zürich, Zurich, Switzerland; regis-
tration number ZH183/2014].
3. Results
3.1. CH25H mRNA expression is a marker of fibrosis 
in intestinal samples of CD patients
To test for a role of the oxysterol synthesising enzyme CH25H in 
CD associated fibrosis, CH25H mRNA expression was measured in 






Gender, n [%] female 7 [100%] 5 [83%]
Age at sample, years [mean, min-max] 36[26–65] 72.7[67–82]
Disease duration, years, [mean,  
min-max]
9.6[1–35] NA
Montreal age at diagnosis, n [%]   
17–40 years [A2] 7 [100%] NA
Montreal disease behaviour, n [%]   
Stricturing disease [B2] 7 [100%] NA
Disease location, n [%]   
Terminal ileum [L1] 4 [57%] NA
Ileocolon [L3] 3 [43%]
C-reactive protein before operation, 
n [%]
  
C-reactive protein >5 mg/L 2 [28%] NA
C-reactive protein <5 mg/L 3 [43%]
Missing 2 [29%]
Clinical disease activity before  
operation, n [%]
  
Disease in remission 0 [0%] NA
Mild disease 1 [14%]
Moderate disease 3 [43%]
Severe disease 3 [43%]
Medication, n [%]   
Corticosteroids 4 [57%]  
Azathioprine/6-mercaptopurine 3 [43%] NA
Anti-TNF 0 [0%]
Anti-IL12/23 1 [14%]
NA, non-applicable; CD, Crohn’s disease; min-max, minimum to max-
imum; TNF, tumour necrosis factor.
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human intestinal surgical samples. We investigated terminal ileum 
samples from CD patients undergoing ileocaecal resection due to 
stenosis. Samples macroscopically affected by fibrosis were compared 
with the proximal ileal resection margin which showed no macro-
scopic signs of fibrosis or inflammation. Healthy tissue, from cancer-
free resection margins of colon adenocarcinoma patients undergoing 
right-sided hemicolectomy, was used as additional control [Table 1]. 
Representative Sirius Red-staining pictures illustrate increased collagen 
deposition in fibrotic areas of CD patients [Figure 1A]. We observed 
a gradual increase of CH25H mRNA expression from control tissue 
to non-fibrotic CD tissue and to fibrotic areas from the same patients 
[p <0.05, Figure 1B]. Thereby, mRNA levels of CH25H strongly cor-
related with the expression levels of fibrosis markers including COL-1 
and -3, SMA, and TGF-β [Figure 1C–F], confirming the association 
of CH25H expression with intestinal fibrosis in the human intestine.
Of note, control patients were older than patients with CD with 
or without fibrosis. This is expected since the incidence of CD peaks 
at a younger age than colorectal carcinoma, and elderly CD pa-
tients are at lower risk for strictures than younger individuals.44,45 
However, it is unlikely to explain the observed difference in CH25H 
expression, since regulation of CH25H does not depend on age.46
3.2. Reduced intestinal fibrosis in mice with 
deficient 25-hydroxycholesterol synthesis
To further investigate the role of CH25H in intestinal fibrosis, we in-
vestigated whether absence of CH25H would reduce fibrosis in dex-
tran sodium sulphate [DSS]-induced chronic colitis, a well-established 
model of intestinal inflammation, typically associated with high levels 
of intestinal fibrosis.17,18 For this aim, we induced chronic colon in-
flammation and fibrosis in wild-type [WT] and Ch25h-/- littermate 
mice, with four cycles of 7 days 2.5% DSS in drinking water followed 
by a 10-day recovery period with normal drinking water. Collagen 
deposition was determined by Sirius Red staining and analysis under 
transmission light microscopy [Figure 2A]. Reduced collagen depos-
ition in Ch25h knockout mice was demonstrated by automated quan-
tification of the collagen layer area [Figure 2B, C]. Further, the collagen 
layer was significantly thinner in DSS-treated Ch25h-/- mice compared 
with WT littermate DSS-treated animals: WT: 22.4 µm ± 7.2, Ch25h-/-: 
11.7 µm ± 2.6, p = 0.008]. In water controls, in the absence of in-
flammation, the baseline collagen layer is indistinguishable from wild-
type animals [Figure 2D, water animals: WT: 8.5 µm ± 2.1, Ch25h-/-: 
8.7 µm ± 0.8, p = 0.17]. Microscopy analysis and histological scoring 
of inflammation [see below] did not reveal any differences between 
non-inflamed wild-type and Ch25h-/- animals.
Additionally, mRNA expression levels for fibrosis markers such 
as Tgf-β, collagen type 3 [Col-3] and Timp-1 were significantly lower 
in the colon of Ch25h-/- animals, and a clear trend for lower mRNA 
expression of collagen type 1 [Col-1] and lysyl oxidase homologue 
2 [Loxl-2] in CH25H-deficient mice was found [Figure 2E–J]. 
Immunohistochemistry demonstrated high α-SMA expression in 
fibrotic sections of wild-type animals and reduced α-SMA expres-
sion in CH25H-deficient mice [Supplementary Figure S1, available 
as Supplementary data at ECCO-JCC online]. Expression levels of 
Ch25h were increased in DSS-treated animals compared with water 
controls [Figure 2J].
Of note, thinner collagen layers and lower expression levels of fi-
brosis markers [Tgf-β, Col-3, and Timp-1] upon Ch25h knockout were 
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Figure 1. Upregulation of CH25H mRNA expression in human fibrotic tissue of patients with CD. [A] Representative images of Sirius Red-stained human ileum 
samples from healthy controls [left panel] and CD patients in a non-fibrotic [middle panel] and in a fibrotic region [right panel]. Scale bar: 2.5 mm. White: CD 
fibrotic, [n = 6], grey: CD non-fibrotic [n = 7], black: healthy control [n = 6]. [B] Samples were analysed for CH25H mRNA expression and normalised to GAPDH. 
CH25H mRNA level was correlated with mRNA levels of [C] Col1, [D] Col3 [E] SMA, and [F] TGFB. Statistical analysis: B: Kruskal-Wallis test; **p <0.01. CD, Crohn’s 
disease. C-E: correlation analysis: Spearman R [non-parametric correlation].
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Figure 2. Reduced fibrosis in Ch25h-/- mice in chronic DSS colitis. Ch25h-/- and WT female mice were treated for four cycles with 2.5% DSS or water [controls]. [A] 
Representative transmission light images of Sirius Red-stained intestinal sections of wild-type [WT] and Ch25h-/- dextran sodium sulphate [DSS]-treated mice 
and water littermate controls. Scale bar: 100 μm. [B] Image analysis for identification of collagen layer areas in the colon mucosa using Matlab custom-made 
scripts. Left panel: Original transmission light Sirius Red-stained image. Right panel: Collagen layer area. [C] Quantification of collagen layer area in DSS-treated 
animals using customised Matlab scripts. [D] Collagen layer thickness calculated from eight or more positions per graft in representative areas of Sirius Red-
stained slides with transmission light at 200-fold magnification. The colon was analysed for mRNA expression of: [E] Tgf-beta, [F] Col3, [G] Col1, [H] Loxl2, [I] 
Timp1, and [J] Ch25h [normalised to Gapdh]. Expression levels are normalised to water-treated wild-type controls. Statistical analysis: Mann-Whitney U test; 
*p <0.05. n = 4–6 per group.
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not due to reduced inflammation: when colon inflammation was ana-
lysed in H/E stained colon sections, the histology score quantifying the 
inflammatory infiltrate and the epithelial damage, was even higher in 
Ch25h-/- mice compared with WT littermates [Figure 3A]. Further, 
macroscopic aspects of intestinal inflammation, such as spleen weight 
and the murine endoscopic index of colitis severity [MEICS], did not 
differ between both genotypes [Figure 3B], with similar thickening of the 
colonic surface (2.30 points ± 0.57 [n = 6] vs 2.25 points ± 0.82 [n = 5], 
p  >0.05, Supplementary Figure S2A, B, available as Supplementary 
data at ECCO-JCC online). Detailed measurements of the muscula-
ris mucosae and external muscle layer did not yield significant differ-
ences between genotypes [Supplementary Figure S2C–E, available as 
Supplementary data at ECCO-JCC online]. In summary, in chronic 
DSS colitis, intestinal collagen deposition was reduced in the absence 
of CH25H, independently of effects of CH25H knockout on intestinal 
inflammation.
3.3. Reduced intestinal fibrosis in the absence 
of CH25H in a heterotopic transplant model of 
intestinal fibrosis
To confirm a role of CH25H in intestinal fibrosis in an inflammation-
independent model, we employed a recently developed heterotopic 
transplant model of intestinal fibrosis.19,20 Sections of small intestine, 
from either CH25H knockout [Ch25h-/-] mice or their wild-type lit-
termate controls [WT], were transplanted subcutaneously into the 
neck of recipient mice of the same genotype.19,20 Non-transplanted 
small bowel sections from Ch25h-/- mice and WT littermates were 
used as controls [Day 0]. Seven days after surgery, the intestinal grafts 
were collected for analysis [Day 7] and collagen deposition was de-
termined by Sirius Red staining under transmission light microscopy. 
At baseline [Day 0], cross sections of WT and Ch25h-/- were histo-
logically indistinguishable, with intact epithelial crypts and a thin 
collagen layer. Seven days following transplantation, occlusion of the 
intestinal lumen and a significantly thicker collagen layer were ob-
served [Figure 4A, overview]. We also confirmed partial destruction 
of the intestinal epithelial layer with loss of epithelial cells 7 days after 
transplantation [Figure 4A, detail] compared with freshly isolated 
tissue on Day 0 [Figure 4A, detail], as expected for this model.19,20
The development of intestinal fibrosis was significantly reduced 
in mice deficient for CH25H, indicated by a significantly thinner 
collagen layer compared with WT littermate controls (Figure 4A, 
B; Day 0: WT: 8.5  µm  ±  0.7, Ch25h-/-: 8.3  µm  ±  1.5 non-signifi-
cant [n.s.], Day 7: WT 15.0  µm  ±  3.1, Ch25h-/-: 12.1  µm  ±  2.3, 
p = 0.01). A thinner collagen deposition in Ch25h knockout mice 
was confirmed by polarised light microscopy with automated 
image analysis and quantification of the collagen layer area [Figure 
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Figure 3. Reduced levels of intestinal fibrosis in CH25H-deficient mice is not due to reduced inflammation in chronic DSS colitis. Analysis of colon inflammation 
in H/E-stained colon sections. [A] Score of the inflammatory infiltrate [left panel], score for epithelial damage [middle panel], and total histology score [sum of 
both partial scores, right panel]. [B] Murine endoscopic index of colitis severity [MEICS] score [left panel] and spleen weight [right panel]. [C] Representative 
H/E-stained sections of the distal colon of water control mice [left panel] and DSS-treated mice. DSS, dextran sodium sulphate; H/E: haematoxylin and eosin.
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Figure 4. Reduced levels of intestinal fibrosis in CH25H-deficient mice in the heterotopic transplantation model. Wild-type and Ch25h-/- animals were tested in a 
heterotopic transplantation model for intestinal fibrosis. [A] Left panels: Overview [low-resolution image] of Sirius Red-stained intestinal grafts of WT and Ch25h-/- mice 
at Day 7 after transplantation. Scale bar: 1 mm. Middle panels: Representative transmission light images demonstrating increased collagen layer thickness in grafts at 
Day 7 compared with freshly isolated intestines at Day 0. Upper panels: WT littermate controls. Lower panels: Ch25h-/-. Scale bar: 50 μm. Right panels: High-resolution 
inserts illustrating measurements of collagen layer thickness. [B] Collagen layer thickness calculated from eight or more positions per graft in representative areas 
of Sirius Red-stained slides with transmission light at 200-fold magnification. [C] Image analysis for identification of collagen layer areas using Matlab custom-made 
scripts. Left panel: Original polarised 200x light microscopy image. Middle panel: Collagen layer area. Right panel: Remaining non-collagen tissue. Scale bar: 50 μm. 
[D] Quantification of collagen layer area at Day 7 post transplantation, using the same strategy as in [C]. [E] Collagen quantification with hydroxyproline assay. Day 0, 
freshly isolated intestine. Day 7, intestine 7 days post transplantation [nWT day 0 = 3, nKO day 0 = 9, nWT day 7 = 8, nWT day 7 = 11]. Statistical analysis: Mann-Whitney U 
test; *p <0.05, **p <0.01. Bars indicate mean ± standard error of the mean [SEM]. WT, wild type; CH25H, cholesterol 25 hydroxylase; HYP, hydroxyproline.
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hydroxyproline was significantly lower in Ch25h knockout intes-
tinal transplants compared with WT littermate controls [Figure 4E].
Ch25h mRNA expression was significantly increased in fi-
brotic small bowel resections 7  days after transplantation com-
pared with freshly isolated intestine [Figure 5A]. Similarly, fibrosis 
markers including Col-1, Mmp-9, and Timp-1 were induced 7 days 
after transplantation compared with Day 0 [Figure 5B–D]. Ch25h-/-  
animals displayed a non-significant trend for reduced expression 
of fibrosis markers compared with WT controls at Day 7 [Figure 
5B–D]. TGF-β protein levels were decreased in Ch25h knockout as 
compared with WT mice, in line with reduced stimulation of pro-
fibrotic pathways upon CH25H deficiency [Figure 5E, F]. Thus, in 
agreement with the DSS-induced chronic colitis model, our hetero-
topic transplant model confirms reduced intestinal fibrosis in the ab-
sence of CH25H.
3.4. Recruitment of immune cells into fibrotic small 
intestine in wild-type and Ch25h-/- animals
To address changes in immune cells infiltrating the intestinal grafts, 
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p = 0.05
Figure 5. Expression of intestinal fibrosis markers in wild-type and Ch25h-/- mice. Wild-type and Ch25h-/- mice were tested in a heterotopic intestinal transplant 
model. Freshly isolated intestines [Day 0] and grafts 7 days after transplantation were analysed for mRNA expression of: [A] Ch25h, [B] Col1, [C] Mmp9, and [D] 
Timp1 [normalised to Gapdh]. [E, F] Analysis of protein expression of TGF-β by Western blot. Statistical analysis: A-D: Mann-Whitney U test; *p <0.05, **p <0.01 
[nWT day 0 = 3, nKO day 0 = 9, nWT day 7 = 8, nWT day 7 = 11]. E-F: n = 4. Unpaired t test.
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7 days after surgery and an explorative mass cytometry [Cytometry 
by Time of Flight, CyTOF] analysis with a broad marker panel 
[Table 2] was performed. Cells were automatically clustered based 
on similarity of surface marker expression. The immune cell infil-
trate was dominated by neutrophils, with a lower fraction of T cells, 
dendritic cells, monocytes, and NK cells [Figure 6A, B]. No signifi-
cant differences between WT and Ch25h-/- animals were detected for 
the investigated immune cell populations [Figure 6C]. Additionally, 
histological analysis of IL-17 revealed no differences in IL-17 ex-
pression between WT and Ch25h-/- grafts [Supplementary Figure S3, 
available as Supplementary data at ECCO-JCC online].
To determine the location of Ch25h mRNA expression in the small 
intestine, RNA in situ hybridisation using fixed-frozen sections of intes-
tinal grafts and freshly isolated intestines was performed. Ch25h mRNA 
expression was detected in freshly isolated intestines from WT mice and 
the graft at 7 days after transplantation [Figure 7A, B, Supplementary 
Figure S4, available as Supplementary data at ECCO-JCC online].
The Ch25h signal appears to be cytoplasmic with the formation of 
small clusters. Ch25h expression was observed in fibroblasts demarcat-
ing the necrotic former mucosa layer, but remains of epithelial crypts 
were not found in the demarcation zone. The Ch25h-expressing, spin-
dle-shaped fibroblasts are arranged in a band-like fascicle with large 
ovoid nuclei exhibiting a thinly dispersed chromatin structure and a 
delicate nuclear membrane without the indentations typically found 
in the nuclei of histiocytes [Figure 7B, arrows]. In contrast, Ch25h is 
not expressed in the inflammatory infiltrate, which mainly consists of 
neutrophils showing characteristic segmented nuclei [Figure 7B, double 
arrows]. No Ch25h-expressing lymphocytes were found. When both 
Ch25h expression and a-SMA were simultaneously assessed, signifi-
cant co-localisation of both markers was found, in line with a fibroblast 
origin of Ch25h-expressing cells [Figure 7C].
3.5. 25-HC does not induce myofibroblast 
differentiation in vitro
To address direct effects of the CH25H product 25-HC on fibro-
blasts, we performed cell culture experiments using primary murine 
intestinal fibroblasts using a protocol similar to a previous study in 
a human lung fetal fibroblast cell line [HFL-1] .39 Addition of TGF-β 
resulted in increased α-SMA protein expression in intestinal fibro-
blasts. In contrast, exposure to 25-HC did not affect α-SMA ex-
pression at 25-HC concentrations of 0.001–0.1 μM [Figure 7D], a 
concentration range covering values determined in human plasma 
before and after LPS exposure [0.01–0.025  μM] .34 When higher 
oxysterol concentrations of 1–10 μM were tested, expression of the 
housekeeping gene β-actin was affected [Figure 7D]; results at such 
a high concentration range should be interpreted very cautiously.47 
Similarly, addition of 25-HC to 3T3 cells did not cause a significant 
increase of α-SMA expression at concentrations of 0.001–0.1 μM 
[Figure 7D].
4. Discussion
In this study, we demonstrate a role of the oxysterol synthesising 
enzyme CH25H in the pathogenesis of intestinal fibrosis. mRNA 
expression of CH25H was upregulated in human intestinal fibrotic 
tissue of CD patients compared with healthy controls, and we found 
a positive correlation between expression of various fibrosis media-
tors and CH25H expression. Further, we demonstrate a contribu-
tion of CH25H to the development of intestinal fibrosis in two 
murine fibrosis models: in the DSS-induced colitis model, which 
is commonly used as a model of chronic intestinal inflammation 
and fibrosis,17,18 mice lacking the CH25H enzyme showed less col-
lagen deposition and lower mRNA levels of fibrosis mediators. In 
the recently developed heterotopic transplantation model, lack of 
CH25H also reduced intestinal collagen deposition as well as levels 
of the collagen metabolite HYP and the crucial pro-fibrotic factor 
TGF-β.48,49 The HYP assay is not available for the chronic DSS colitis 
model, which is a limitation of our study.
In several aspects, the newly developed heterotopic transplanta-
tion model complements the DSS-induced model. The DSS-induced 
fibrosis model is well-established50 and chronic DSS colitis, with 
cycles of DSS exposure and recovery, reflects many aspects of human 
CD with episodes of inflammation and recovery, leading to tissue 
remodelling and fibrosis. In DSS colitis, fibrosis is induced by dis-
ruption of the integrity of the mucosal barrier, resulting in bacterial 
translocation and lymphocyte infiltration, which promotes chronic 
colon inflammation. In this model, fibrosis has been assessed by 
microscopic imaging of collagen staining in the mucosa and submu-
cosa, measurements of collagen metabolites [hydroxyproline assay], 
and magnetic resonance imaging [MRI] relaxometry.51–53 Induction 
of fibrosis upon DSS exposure might depend on the mouse geno-
type51 and can be observed after a single cycle of DSS treatment,51,53 
even though fibrosis further increases following 2 weeks of recovery 
and repeated DSS exposure.52 The 2,4,6,-trinitrobenzene sulphonic 
acid [TNBS]-induced colitis is a colitis model that might better 
resemble human CD regarding transmural inflammation and induc-
tion of the adaptive immune response,54 but is associated with other 
inherent limitations.55
In the heterotopic transplantation model, fibrosis is reliably in-
duced within 7 days after transplantation. In contrast to DSS colitis, 
features of the transplantation model include occlusion of the lumen 
[reminiscent of human intestinal stenosis] and fibrosis of the small 
intestine, the organ most frequently involved in human CD. This new 
model also reflects other important aspects of the human disease, 
such as activation of intestinal myofibroblasts, expression of IL-13, 
TGF-β and α-SMA, and collagen deposition in the extracellular 
matrix.20 In the transplantation model, fibrosis is associated with 
Table 2. Antibodies used for CyTOF analysis.
Name Clone Reactivity Tag
Ly6G 1A8 Mouse 141Pr
CD11c N418 Mouse 142Nd
CD115 AFS98 Mouse 144Nd
CD69 H1.2F3 Mouse 145Nd
CD45 30-F11 Mouse 147Sm
CD11b [MAC1] M1/70 Mouse 148Nd
CD19 6D5 Mouse 149Sm
Ly6C HK1.4 Mouse 150Nd
CD25 3C7 Mouse 151Eu
CD3e 145-2C11 Mouse 152Sm
CD335, NKp46 29A1.4 Mouse 153Eu
CD62L MEL-14 Mouse 160Gd
CCR7 4B12 Mouse 163Dy
CD8a 53–6.7 Mouse 168Er
TCRβ H57-597 Mouse 169Tm
NK1.1 PK136 Mouse 170Er
CD44 IM7 Mouse, human 171Yb
CD4 RM4-5 Mouse 172Yb
I-A/I-E M5/144 Mouse 174Yb
B220 RA3-6B2 Mouse 176Yb
All antibodies were pre-labelled [Fluidigm].
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Figure 6. Cells infiltrating the graft do not differ between wild-type and CH25H-deficient mice. Lamina propria infiltrating cells from grafts of wild-type and 
Ch25h-/- mice were harvested 7 days after surgery and analysed by CyTOF. [A] Dimensionality-reduced projection of the entire phenotypical landscape was 
calculated using the tSNE algorithm with Barnes-Hut approximation [bhSNE]. The colour coding represents staining intensity of the specified marker. [B] t-SNE 
maps of each experimental group; 250 000 randomly selected points are plotted. Overlaid in colour are cluster designations computed by the Phenograph 
clustering algorithm. The represented clusters were manually constructed by merging the initial cluster output based on phenotypical similarity until the final 
number of 11 identifiable clusters was reached. [C] Bar plot showing the mean cluster frequencies and error bars representing standard error of the mean [SEM] 
[nWT = 5, nKO = 5].
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Figure 7. Expression of Ch25h in fibroblasts in intestinal grafts. [A] Representative images of the in situ hybridisation [RNAscope] analysis of wild-type small 
intestine. Negative control [a probe for the bacterial gene dihydrodipicolinate reductase, Dapb, left panel] and Ch25h mRNA [middle panel] are demonstrated 
with the RNAscope signal shown in red. Right panel: High resolution of inserts of the RNAscope signal. Scale bar: 25 μm. [B] Representative images of the Ch25h 
RNAscope analysis of the intestinal grafts of wild-type [WT] mice at Day 7 after transplantation, demonstrating accumulation of the CH25H signal in fibroblasts 
in the former mucosa layer. Scale bar left panel: 20 μm, middle panel: 50 μm. The right panel shows inserts of the middle panel. Fibroblasts are indicated by 
arrows, neutrophils by a double arrow. [C] Overlay of Ch25h RNAscope analysis and the α-SMA staining from two representative images with enlarged inserts. 
Scale bar: 100 μm, scale bar insert: 20 μm. [D] 3T3 cells [left panel] and primary mouse intestinal fibroblasts [right panel] were treated for 72 h with different 
concentrations of 25-HC and/or TGF-β as indicated. Samples were analysed for α-SMA protein levels by Western blot. Expression levels are normalised relative 
to the negative control and shown as mean ± standard error of the mean [SEM]. Statistical analysis: unpaired t test, the * is relative to the negative control; 
*p <0.05, **p <0.01, n = 2.
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ischaemia and hypoxia, increased expression of Hif1α, and neo-
vascularisation. However, bacterial translocation and the pathogen 
associated molecular pattern [PAMP]-associated signalling is not a 
prerequisite of fibrosis in this model, as collagen deposition is also 
increased following transplantation of small bowel from germ-free 
mice and MyD88-deficient mice.56 In the heterotopic transplant 
model, fibrosis is also observed in the absence of B and T cells in 
RAG2-deficient mice [M. Hausmann, unpublished observations].
There is general consensus that currently there is no animal model 
available which would reflect all aspects of human CD-associated 
intestinal fibrosis.50,54,55 However, in DSS colitis and small intesti-
nal heterotopic transplantation, complementary clinical features 
can be studied and fibrosis seems to be induced by different path-
ways. Robust reduction of fibrosis upon CH25H knockout in two 
independent fibrosis models clearly strengthens the validity of our 
findings.
Our data demonstrate Ch25h expression in local fibroblasts in 
intestinal grafts, which potentially leads to local 25-HC production 
by fibroblasts. However, it remains unclear which cell[s] respond to 
25-HC during fibrosis induction. In a previous in vitro study, 25-HC 
induced nuclear factor-κB [NF-κB] activation and subsequent release 
of TGF-β in human fetal lung fibroblasts, ultimately leading to α-
SMA expression and myofibroblast differentiation.39 In support of 
this finding, activation of NF-κB by 25-HC was also demonstrated 
in primary rat hepatocytes and in a human monocytic cell line.57,58 
However in our study, addition of 25-HC to 3T3 fibroblasts or pri-
mary murine intestinal fibroblasts failed to induce α-SMA expres-
sion. Therefore in the intestine, cells different from fibroblasts might 
be responsible for TGF-β production upon 25-HC exposure.
Previous reports demonstrated that 25-HC inhibits Th17 cell 
differentiation,24,59 and Ch25h knockout mice have higher numbers 
of Th17 cells in peripheral lymph nodes and the spleen.60 Th17-
derived IL-17 is a key driver of fibrosis in different organs, includ-
ing the gut.61–63 However, histological analysis and quantification 
of IL-17 revealed no differences between WT and Ch25h-/- intesti-
nal grafts. Further, our histological analysis revealed no decrease in 
intestinal inflammation between wild-type and Ch25h-/- littermate 
controls in chronic DSS colitis [Figure 3] and acute DSS colitis,64 
which further supports that CH25H knockout does not simply 
reduce fibrosis by diminishing overall intestinal inflammation. In 
line with these results, the numbers of CD4-positive cells in grafts 
from WT and Ch25h knockout animals were similar. In fact, with 
the antibody panel used in the CYTOF-analysis, the inflammatory 
infiltrate in intestinal grafts could not be distinguished between 
mice of both genotypes, which is well in line with involvement of 
CH25H in pro-fibrotic pathways independent of intestinal inflam-
mation. However, our CYTOF analyses do not distinguish several 
cellular subtypes of the infiltrate. For instance, the compartment 
of myeloid mononuclear cells including dendritic cells [DCs] and 
macrophages has not been characterised in detail. Effects of mac-
rophages on intestinal fibrosis have been demonstrated,65,66 and our 
results do not exclude a modulation of frequency, activation level, 
and/ or phenotype of macrophages or DCs, which remains a limita-
tion of our study.
The CH25H product 25-HC has been shown to modulate several 
immune responses.21,23,25,28,29,33 25-HC acts as an acute defence mol-
ecule and a master regulator of inflammation by increasing antiviral 
responses28–30,67 and decreasing antibacterial defence mechanisms.33,55 
Our study suggests an additional role of the oxysterol 25-HC as 
a mediator of intestinal fibrosis. The induction of wound healing, 
which potentially leads to fibrosis, might thus start very early in the 
inflammatory cascade by the acute immune-modulatory activity of 
25-HC, which is rapidly induced after an inflammatory stimulus.68
Despite advances in the treatment of CD-associated inflamma-
tion, a specific intestinal anti-fibrotic therapy remains an unmet 
clinical need.7,8 To the best of our knowledge, no specific CH25H 
inhibitor is available. However, desmosterol has been shown to 
reduce enzymatic activity of CH25H in a seminal paper,32 and 
subsequent cell culture studies69,70 and compounds leading to des-
mosterol accumulation in vivo exist.71 In other studies, a potential 
25-HC inhibitor [LY295427, agisterol] was shown to antagonise 
cholesterol-homeostatic effects of 25-HC.72,73 Finally, caffeic acid 
phenethyl esther [CAPE], a natural derivate from several plants 
as well as propolis from honey bee hives, is a powerful and spe-
cific NF-kB inhibitor74–76 and was able to block 25-HC-mediated 
NF-kB activation in cell culture.39 CAPE was able to inhibit 
myofibroblast formation and collagen synthesis in human fibro-
blasts,39,77 animal models of hepatic fibrosis models,78,79 and pul-
monary fibrosis.80,81
Importantly, our experiment only addressed inhibition of the 
development of intestinal fibrosis, and the role of CH25H in the 
reversal of fibrosis remains unclear. Further, inhibition of wound 
healing/ fibrosis might inadvertently promote penetrating/ fistulising 
disease in intestinal inflammation. These concerns will have to be 
addressed by future animal studies.
In summary, our findings implicate the hydroxylase CH25H 
in intestinal fibrosis, making CH25H a potential promising novel 
therapeutic target to prevent intestinal fibrosis, but additional stud-
ies are required to elucidate the exact mechanism by which CH25H 
promotes fibrosis.
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